Brokerages expect Selecta Biosciences, Inc. (NASDAQ:SELB) to report earnings of ($0.86) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Selecta Biosciences’ earnings. Selecta Biosciences posted earnings of ($2.75) per share in the same quarter last year, which would indicate a positive year over year growth rate of 68.7%. The firm is expected to issue its next quarterly earnings results on Tuesday, August 8th.

On average, analysts expect that Selecta Biosciences will report full year earnings of ($2.63) per share for the current fiscal year. For the next year, analysts expect that the company will report earnings of ($3.14) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Selecta Biosciences.

Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings results on Thursday, May 11th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.40. The company had revenue of $0.14 million during the quarter. Selecta Biosciences had a negative net margin of 715.40% and a negative return on equity of 76.21%.

Several analysts have issued reports on SELB shares. Zacks Investment Research cut shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 1st. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Selecta Biosciences in a research note on Tuesday, March 28th. ValuEngine upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 30th. Finally, Canaccord Genuity set a $25.00 target price on shares of Selecta Biosciences and gave the stock a “buy” rating in a research note on Saturday, May 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $26.00.

Shares of Selecta Biosciences (NASDAQ:SELB) traded down 0.15% on Thursday, reaching $19.55. 51,825 shares of the company were exchanged. The firm has a 50 day moving average price of $15.41 and a 200-day moving average price of $14.83. Selecta Biosciences has a 12-month low of $10.26 and a 12-month high of $28.00.

In other Selecta Biosciences news, CFO David Siewers sold 7,420 shares of the stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $20.00, for a total value of $148,400.00. Following the sale, the chief financial officer now directly owns 7,420 shares in the company, valued at approximately $148,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Lloyd P. Johnston sold 13,205 shares of the stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $13.95, for a total transaction of $184,209.75. Following the completion of the sale, the chief operating officer now owns 14,811 shares in the company, valued at $206,613.45. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 355,413 shares of company stock worth $6,232,567 and sold 329,065 shares worth $4,835,887.

A number of hedge funds have recently bought and sold shares of SELB. Candriam Luxembourg S.C.A. purchased a new stake in Selecta Biosciences during the first quarter valued at about $444,000. Goldman Sachs Group Inc. boosted its stake in Selecta Biosciences by 83.1% in the first quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock valued at $452,000 after buying an additional 14,332 shares in the last quarter. UBS Group AG boosted its stake in Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock valued at $1,022,000 after buying an additional 65,938 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Selecta Biosciences during the first quarter valued at about $211,000. Finally, Hikari Power Ltd purchased a new stake in Selecta Biosciences during the first quarter valued at about $349,000. Institutional investors and hedge funds own 46.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/07/16/0-86-earnings-per-share-expected-for-selecta-biosciences-inc-nasdaqselb-this-quarter-updated.html.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.